Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in CashFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Goldenwell Biotech (GWLL) Cash from Financing Activities (2019 - 2024)

Goldenwell Biotech's Cash from Financing Activities history spans 5 years, with the latest figure at $70000.0 for Q4 2024.

  • For Q4 2024, Cash from Financing Activities rose 15.92% year-over-year to $70000.0; the TTM value through Sep 2025 reached $67900.0, down 38.07%, while the annual FY2024 figure was $119250.0, 0.95% down from the prior year.
  • Cash from Financing Activities reached $70000.0 in Q4 2024 per GWLL's latest filing, up from -$2100.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $170125.0 in Q1 2021 to a low of -$2100.0 in Q3 2024.
  • Average Cash from Financing Activities over 4 years is $53471.6, with a median of $30000.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: soared 2230.48% in 2021, then crashed 107.0% in 2024.
  • A 4-year view of Cash from Financing Activities shows it stood at $1000.0 in 2020, then skyrocketed by 16912.5% to $170125.0 in 2021, then tumbled by 64.5% to $60388.0 in 2023, then rose by 15.92% to $70000.0 in 2024.
  • Per Business Quant, the three most recent readings for GWLL's Cash from Financing Activities are $70000.0 (Q4 2024), -$2100.0 (Q3 2024), and $49250.0 (Q2 2024).